Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 3 institutions in 2 countries.
Mateus S LopesPost-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.
Gabriel B BaptistellaDepartment of Chemistry, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.ORCID 0000-0002-7601-2038
Giovana G NunesDepartment of Chemistry, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.ORCID 0000-0001-7052-2523
Matheus V FerreiraPost-Graduation Program in Pharmacology, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.
Joice Maria CunhaPost-Graduation Program in Pharmacology, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.ORCID 0000-0003-0897-091X
Kauê Marcel de OliveiraPost-Graduation Program in Pharmacology, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.
Alexandra AccoPost-Graduation Program in Pharmacology, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.ORCID 0000-0003-3977-687X
Maria Luiza C LopesPost-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.
Alexessander Couto AlvesSchool of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK.ORCID 0000-0001-8519-7356
Glaucio ValdameriPost-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.ORCID 0000-0003-1882-1512
Vivian R MourePost-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.
Geraldo PichethPost-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.
Graciele C M ManicaDepartment of Bioscience One Health of Federal University of Santa Catarina, Curitibanos 88520-000, SC, Brazil.
Fabiane G M RegoPost-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.ORCID 0000-0003-1726-8524
Universidade Federal do Paraná · BRUniversidade Federal de Santa Catarina · BRUniversity of Surrey · GB
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance Code 001National Council for Scientific and Technological Development 405105/2021-5 and 310290/2021-0
6 · The paper itself
Abstract
Diabetes mellitus (DM) complications are a burden to health care systems due to the associated consequences of poor glycemic control and the side effects of insulin therapy. Recently. adjuvant therapies, such as vanadium compounds, have gained attention due to their potential to improve glucose homeostasis in patients with diabetes. In order to determine the anti-diabetic and antioxidant effects of the oxidovanadium(IV) complex (Et
Indexed as
adjunctive to insulin therapiesoxidovanadium(IV)STZ-induced diabetic ratstreatment efficacyvanadium
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
A Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats. · full record | Socratic